General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Consolidated revenue for the June 2026 quarter came in at ₹178.67 crore against ₹33.39 crore a year earlier — a 435% jump, which sounds heroic until you learn that the year-ago quarter simply didn’t contain an Australian company. Noumed was consolidated from 12 November 2025, and management said plainly that the year-on-year comparison is not like-for-like. Two quarters of the enlarged base exist. This is the second.
Operating profit was ₹23.52 crore, PAT ₹7.92 crore, EPS ₹1.79. Sequentially, revenue slipped from ₹197.93 crore and PAT from ₹13.16 crore, which management attributed to lower revenue and a normalized tax charge — the March quarter had carried a tax line of negative ₹0.76 crore, an arrangement that tends not to repeat.
The board meeting of 11 August ran to eighteen items, which for a company four months into its listed life is a brisk pace of governance. Among them: ₹101.85 crore of IPO proceeds proposed to be pointed at two entirely different assets than the prospectus named, a re-appointment, a resignation, an ESOP ratification, and the incorporation of an American subsidiary that management described as “too premature” to have a strategy.
FY26 closed with revenue of ₹381 crore, PAT of ₹14.26 crore, and cash and bank of ₹416.97 crore against ₹2.09 crore a year earlier. Balance sheets do not usually change size like that without help.
2. Introduction
Sai Parenteral’s Ltd was incorporated in 2001 and, per the company, has evolved from a parenteral-focused player into a diversified formulations platform, reducing its dependency on injectables along the way — a company named after injectables gradually making itself less about injectables, which is the pharmaceutical equivalent of a band outgrowing its first album.
The listed history is short. The IPO completed in March 2026 with a primary raise of ₹285 crore, and the shares listed on 2 April 2026. The company was not required to publish quarterly results for the June 2025 quarter, so that comparative exists only because someone helpfully put it in the statement.
The acquisition record laid out by the company runs: Unit III at Bhongir in FY22 for ₹24 crore, Unit IV at Bollaram in FY23 for ₹11 crore, Revat Laboratories in FY24 for ₹28 crore, and Noumed Pharmaceuticals in FY26 — 74.64% for AUD 22 million, or ₹129 crore. Each acquisition is roughly the size of the last one plus its own ambition. Two more are proposed for FY27: 60% of Saicriti Pharma for ₹83.83 crore and 60% of Prathyak Laboratories for ₹15 crore.
The group now has five subsidiaries, two of them step-down, spread across India, Singapore, Australia and New Zealand, with a sixth entity under incorporation in the United States. The Singapore entity is described in the corporate structure as a holding company for cross-border transactions, which is the most honest job description on the chart.
The June 2026 quarter is therefore the first full one following the AUD 202 million Australian OTC supply agreement effective 1 July 2026 — except it isn’t, because that contract begins contributing in Q2. Q1 predates it by a day.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
Three engines, per the company. CDMO exports, branded generics, and the Noumed platform.
The CDMO business does end-to-end contract development and manufacturing — development, validation, stability, dossiers, international filings, commercial supply. The company states no CDMO work is undertaken domestically; the entire contract book serves export markets. It was 63% of FY26 net revenue against 5% in FY23, a 355.6% CAGR over FY23–FY26, which is what happens when a rounding error decides to become a division. The cycle is slow by construction: roughly 12 to 14 months to develop a product and another 12 to 14 months to secure approval, after which supply typically continues for the life of the registration. Two years of paperwork, then an annuity.
Branded generics — 37% of FY26 net revenue — sells off-patent formulations under the company’s own brands to government agencies, hospitals, super stockists and Jan Aushadhi locations, plus exports through 7 distributors across 10 countries. Institutional share fell from 61% of this vertical in FY23 to 19% in FY26 as private-sector share rose to 81%.
Then Noumed, which is the genuinely unusual bit. Australian retail pharmacy chains own the consumer brands but hold no registrations and do no manufacturing. Noumed holds the marketing authorisation, supplies the private-label product, warehouses it, distributes it, and sells regulatory and pharmacovigilance services back to the same customer. The chains put their name on the box; Noumed owns everything inside and behind it. There are 15 exclusive agreements covering 526 SKUs, and Wesfarmers, EBOS and Sandoz networks cover 2,900 of Australia’s 5,500 pharmacies. The structural quirk that makes this work: in Australia, molecules like metformin, loratadine and naproxen sell
